In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.

●Consolidated net sales totaled 222,584 million yen, an increase of 20,793 million yen (10.3%) year-on-year. Sales in the Mobility & Imaging Business Unit, Fine Chemicals Business Unit, and Life Science Business Unit all outperformed the previous fiscal year.
●Consolidated operating income increased by 13,064 million yen (178.1%) to 20,401 million yen compared to the pre-vious fiscal year.
●Consolidated ordinary income totaled 22,266 million yen, an increase of 9,704 million yen (77.3%) year-on-year. The increase was due to growth in consolidated operating income which exceeded the decrease in foreign exchange gains.
●Profit attributable to owners of parent was 17,508 million yen, an increase of 13,395 million yen (325.6%) year-on-year. The increase was mainly due to a gain on sales of investment securities.

(millions yen)	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03
Cash flows from operating activities	19,603	31,390	20,121	26,803	27,281	24,408	23,141	20,039	23,242	25,530
Cash flows from investing activities	-5,090	-11,913	-16,171	-17,694	-17,543	-17,606	-10,641	-15,158	-19,409	-27,313
Cash flows from financing activities	-9,432	-14,103	-6,241	-6,437	-13,894	-8,402	-11,090	-7,950	3,823	-4,756
Cash and cash equivalents at the end of period	47,464	51,785	50,532	52,697	46,663	47,483	52,962	53,096	64,777	57,926